evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

28 questions · 28 findings · 6 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 11 · 39.3%GRADE not reported 1 · 3.6%Very low 8 · 28.6%Low 1 · 3.6%Moderate 7 · 25%High 0 · 0%

Azithromycin vs doxycycline

Physician‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Azithromycin vs doxycycline

Assessment of erythema or telangiectasia ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Azithromycin vs doxycycline

Time needed until improvement of the skin lesions · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Azithromycin (500 mg 20 ‐ 28 days) vs meglumine antimoniate (15 ‐ 20 mg/kg/d

Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis

Azithromycin (500 mg 20 ‐ 28 days) probably leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (15 ‐ 20 mg/kg/d (moderate certainty).

1 finding from 1 review